Skip to main content

Peer Review reports

From: A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Original Submission
12 Oct 2014 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
21 Sep 2015 Editorially accepted
6 Oct 2015 Article published 10.1186/s12885-015-1656-4

You can find further information about peer review here.

Back to article page